resources

Senores Pharmaceuticals Ltd.

NSE: SENORES

BSE: 544319

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

1,215.30+12.7 (+1.06%)

23 Oct, 12:00 AM

Overview Analysis Statements Technicals Forecast Peers Resources

News

Annual Reports and Financial Documents

Senores Pharmaceuticals Ltd. annual reports, quarterly results, earnings call transcripts and investor presentations. All official filings in one place.

	2024	2025	2026
Annual Reports	—	FY 2025	FY 2026
Quarterly Results	Dec	Mar Jun Sept Dec	Mar Jun
Conference Calls	—	30Jan 22May 30Jul 13Nov	27Jan 19May 3Aug
Presentations	—	16May 23Jul 6Nov 15Dec	20Jan 14May 27Jul

Corporate Announcements and Regulatory Filings

Senores Pharmaceuticals Ltd. BSE/NSE disclosures, board meeting outcomes, insider trading notifications, acquisitions and other regulatory filings.

Analyst / Investor Meet23 Oct 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
We hereby inform you that the timing of the earnings conference call to discuss the financial results for the second quarter of FY 2026-27 (Q2 FY27) has been re-scheduled to 04:00 P.M. ....
Analyst / Investor Meet22 Oct 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
We hereby inform that, post announcement of Un-audited Consolidated and Standalone Financial Results for the quarter and half year ended on September 30, 2026, the Company will hold the ....
Board Meeting22 Oct 2026
Board Meeting Intimation for Approval Of The Un-Audited Consolidated And Standalone Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2026
Senores Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 ,inter alia, to consider and approve 1. The Un-audited ....
Newspaper Publication17 Oct 2026
Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find enclosed herewith copies of Newspaper publications regarding completion of dispatch of Notice of Postal Ballot, information of e-voting and other related information.
Postal Ballot16 Oct 2026
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Senores Pharmaceuticals Limited has informed the Exchange regarding Notice of Postal Ballot
Change in Management13 Oct 2026
Announcement under Regulation 30 (LODR)-Change in Management
The Board at its meeting held today has re-appointed Mr. Swapnil Jatinbhai Shah as the Managing Director of the Company and Mr. Chetan Bipinchandra Shah as the Whole-time Director of the Company.
Outcome without intimation13 Oct 2026
Board Meeting Outcome for Outcome Of Board Meeting
The Board of Directors of the Company at their Meeting held today i.e., Tuesday, October 13, 2026, has approved the following: 1. Re-Appointment of Mr. Swapnil Jatinbhai Shah (DIN: 05259821) ....
Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 20188 Oct 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Senores Pharmaceuticals Limited has informed the Exchange about the certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018 for the quarter ended September 30, 2026
AGM28 Sept 2026
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Senores Pharmaceuticals Limited has informed the Exchange regarding Scrutinizer Report and Voting results of 09th Annual General Meeting
AGM25 Sept 2026
Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings of the 9th Annual General Meeting of the Company held on September 25, 2026
Closure of Trading Window24 Sept 2026
Closure of Trading Window
Intimation pertaining to closure of trading window
General21 Sept 2026
Clarification On Movement In Volume
Clarification Letter on volume movement in the scrip of the Company
General11 Sept 2026
Successful Completion Of USFDA Inspection
We are pleased to announce that the USFDA has successfully completed its inspection at the manufacturing facility of Apnar Pharma Private Limited
Reg. 34 (1) Annual Report9 Sept 2026
Reg. 34 (1) Annual Report.
We are submitting herewith the Corrigendum to the Annual Report of the Company for the financial year 2025-26.
Newspaper Publication4 Sept 2026
Announcement under Regulation 30 (LODR)-Newspaper Publication
We are enclosing herewith the Newspaper Publication for the 9th Annual General Meeting of the Company.
Business Responsibility and Sustainability Reporting (BRSR)3 Sept 2026
Business Responsibility and Sustainability Reporting (BRSR)
We are submitting herewith the copy of Business Responsibility and Sustainability Report of the Company for the financial year 2025-26.
Reg. 34 (1) Annual Report3 Sept 2026
Reg. 34 (1) Annual Report.
We are submitting herewith the Annual Report of the Company for the financial year 2025-26.
AGM3 Sept 2026
Shareholder Meeting To Be Held On September 25, 2026 At 11:30 Am (IST)
We are submitting herewith the notice convening the 9th Annual general Meeting of the Company and Annual Report for the financial year 2025-26
Analyst / Investor Meet27 Aug 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Senores Pharmaceuticals Limited has informed the Exchange regarding Analyst/ Institutional Investor Meet scheduled to be held on September 02, 2026
Newspaper Publication27 Aug 2026
Announcement under Regulation 30 (LODR)-Newspaper Publication
Senores Pharmaceuticals Limited has informed the Exchange regarding copy of newspaper publication for pre dispatch of Annual Report for the forthcoming Annual General Meeting of the Company

Frequently Asked Questions

Where can I download the annual report of Senores Pharmaceuticals Ltd.?

Annual reports of Senores Pharmaceuticals Ltd. are available for download in the Annual Reports and Financial Documents section of the Resources tab, organised by financial year.

Where can I find the quarterly results of Senores Pharmaceuticals Ltd.?

Quarterly earnings results and presentations of Senores Pharmaceuticals Ltd. are available in the Annual Reports and Financial Documents section of the Resources tab. Detailed financials are also in the Statements tab.

Does Senores Pharmaceuticals Ltd. publish earnings call transcripts?

Earnings call transcripts of Senores Pharmaceuticals Ltd., where available, are listed in the Annual Reports and Financial Documents section of the Resources tab.

Where can I find investor presentations of Senores Pharmaceuticals Ltd.?

Investor presentations and annual day presentations of Senores Pharmaceuticals Ltd. are listed in the Resources tab under Annual Reports and Financial Documents.

What are the recent corporate announcements of Senores Pharmaceuticals Ltd.?

Corporate announcements and regulatory filings of Senores Pharmaceuticals Ltd. as submitted to BSE and NSE are available in the Corporate Announcements and Regulatory Filings section of the Resources tab.

How do I access the regulatory filings of Senores Pharmaceuticals Ltd.?

Regulatory filings including board meeting outcomes, insider trading disclosures and other exchange notifications of Senores Pharmaceuticals Ltd. are in the Corporate Announcements and Regulatory Filings section of the Resources tab.

What is the ISIN of Senores Pharmaceuticals Ltd.?

The ISIN (International Securities Identification Number) of Senores Pharmaceuticals Ltd. is INE0RB801010. This is the unique identifier used across exchanges and depositories.

On which stock exchange is Senores Pharmaceuticals Ltd. listed?

Senores Pharmaceuticals Ltd. is listed on NSE and BSE. The NSE symbol is SENORES and the BSE code is -.

Where can I find the shareholding pattern of Senores Pharmaceuticals Ltd.?

The quarterly shareholding pattern of Senores Pharmaceuticals Ltd. showing promoter, FII, DII, mutual fund and public holdings is available in the Shareholding Pattern section on the Overview tab.

How current is the data for Senores Pharmaceuticals Ltd. on Sharpely?

Share price data for Senores Pharmaceuticals Ltd. is updated as of 23 Oct 2026. Financial statements, shareholding and other fundamental data are updated after each quarterly disclosure.